Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), is expanding its capabilities by licensing ATUM’s miFuc platform designed for expression of recombinant proteins containing afucosylated glycans.
ATUM’s miFuc technology is designed for the development of antibodies with significant reduction in fucosylation without affecting product titer, cellular growth rates, or incurring global glycan liabilities. Enabled by ATUM’s proprietary Leap-In…
Read More…
Wheeler Bio Licenses ATUM’s MiFuc Platform For Afucosylated Antibodies
